John Lunger - Net Worth and Insider Trading
John Lunger Net Worth
The estimated net worth of John Lunger is at least $13,786 dollars as of 2024-11-29. John Lunger is the Chief Patient Supply Officer of Adaptimmune Therapeutics PLC and owns about 19,015 shares of Adaptimmune Therapeutics PLC (ADAP) stock worth over $13,786. Details can be seen in John Lunger's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that John Lunger has not made any transactions after 2024-01-17 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of John Lunger
John Lunger Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, John Lunger owns 3 companies in total, including Adaptimmune Therapeutics PLC (ADAP) , Genocea Biosciences Inc (GNCAQ) , and Genocea Biosciences Inc (GGNNQ) .
Click here to see the complete history of John Lunger’s form 4 insider trades.
Insider Ownership Summary of John Lunger
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ADAP | Adaptimmune Therapeutics PLC | 2024-01-17 | Chief Patient Supply Officer |
| GNCAQ | Genocea Biosciences Inc | 2022-03-03 | director |
| GGNNQ | Genocea Biosciences Inc | 2022-03-03 | director |
John Lunger Latest Holdings Summary
John Lunger currently owns a total of 1 stock. John Lunger owns 19,015 shares of Adaptimmune Therapeutics PLC (ADAP) as of January 17, 2024, with a value of $13,786.
Latest Holdings of John Lunger
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ADAP | Adaptimmune Therapeutics PLC | 2024-01-17 | 19,015 | 0.73 | 13,786 |
Holding Weightings of John Lunger
John Lunger Form 4 Trading Tracker
According to the SEC Form 4 filings, John Lunger has made a total of 17 transactions in Adaptimmune Therapeutics PLC (ADAP) over the past 5 years, including 0 buys and 17 sells. The most-recent trade in Adaptimmune Therapeutics PLC is the sale of 22,795 shares on January 17, 2024, which brought John Lunger around $15,957.
Insider Trading History of John Lunger
- 1
John Lunger Trading Performance
John Lunger Ownership Network
John Lunger Owned Company Details
What does Adaptimmune Therapeutics PLC do?
Who are the key executives at Adaptimmune Therapeutics PLC?
John Lunger is the Chief Patient Supply Officer of Adaptimmune Therapeutics PLC. Other key executives at Adaptimmune Therapeutics PLC include Chief Commercial Officer Cintia Piccina , Chief Medical Officer Elliot Norry , and Chief Operating Officer Bertrand William C Jr .
Adaptimmune Therapeutics PLC (ADAP) Insider Trades Summary
Over the past 18 months, John Lunger made 3 insider transaction in Adaptimmune Therapeutics PLC (ADAP) with a net sale of 35,120. Other recent insider transactions involving Adaptimmune Therapeutics PLC (ADAP) include a net sale of 73,322 shares made by Adrian Rawcliffe , a net sale of 32,818 shares made by Bertrand William C Jr , and a net sale of 32,371 shares made by Elliot Norry .
In summary, during the past 3 months, insiders sold 0 shares of Adaptimmune Therapeutics PLC (ADAP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 245,864 shares of Adaptimmune Therapeutics PLC (ADAP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 245,864 shares.
Adaptimmune Therapeutics PLC (ADAP)'s detailed insider trading history can be found in Insider Trading Tracker table.
Adaptimmune Therapeutics PLC Insider Transactions
John Lunger Mailing Address
Above is the net worth, insider trading, and ownership report for John Lunger. You might contact John Lunger via mailing address: C/o Adaptimmune Therapeutics Plc, 60 Jubilee Ave, Milton Park, Abingdon, Oxfordshire X0 Ox14 4rx.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
